Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MK-2010

Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Vascular endothelial growth factor A (VEGFA) · developed by Merck &

Phase 1/2 Most advanced trial
MRK Developer
1 Registered trials

What is MK-2010?

MK-2010 is a bispecific antibody that binds PD-1 on T-cells and VEGF, blocking PD-1 activation by its ligands PD-L1 and PD-L2 and blocking VEGF binding to VEGFR. It is being studied in recurrent ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
Programmed cell death protein 1 (PDCD1), Vascular endothelial growth factor A (VEGFA), Programmed cell death 1 ligand 1 (CD274) (binding partner it blocks)
Mechanism
Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Vascular endothelial growth factor A (VEGFA)
Pathways
PD-1/PD-L1 immune checkpoint signaling, VEGF/VEGFR signaling, tumor angiogenesis
Therapy area
Oncology
Developer
Merck & Co. (MRK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07793942 Phase 2 Malignant Neoplam Recruiting MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer Recurrent

Other drugs acting on PDCD1 / VEGFA

More from Merck &

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind MK-2010

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.